血清神经生长因子及细胞免疫水平在乳腺癌中的表达及其与临床病理特征的相关性

摘要
图/表
参考文献(22)
相关文章 (15)

全文: PDF (523 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨血清神经生长因子（NGF）及细胞免疫水平在乳腺癌患者中的表达及其与临床病理特征的相关性。方法选择2015年3月～2018年2月在杭州市妇产科医院及浙江省舟山医院确诊的乳腺癌患者49例，设为观察组；选择同期入院的乳腺良性疾病患者45例，设为对照组；选择同期入院健康体检女性47名，设为正常组。采用酶联免疫吸附试验测定各组NGF表达水平；采用流式细胞仪测定各组CD3+、CD4+、CD8+及CD4+/CD8+水平；记录并统计患者临床病理资料，分析各组和观察组乳腺癌不同临床病理资料的NGF、细胞免疫水平；采用Pearson分析NGF、细胞免疫水平与乳腺癌患者临床病理资料的相关性。结果三组NGF、细胞免疫水平比较，差异均有统计学意义（P ＜ 0.05）。观察组NGF水平高于对照组与正常组，且对照组NGF水平高于正常组，差异均有统计学意义（P ＜ 0.05）。观察组CD3+、CD4+及CD4+/CD8+水平低于对照组与正常组，CD8+水平高于对照组与正常组，差异均有统计学意义（P ＜ 0.05）；对照组与正常组CD3+、CD4+、CD8+及CD4+/CD8+水平比较，差异无统计学意义（P ＞ 0.05）。乳腺癌组织中NGF、CD3+、CD4+、CD8+及CD4+/CD8+水平在年龄、病理组织学类型方面比较，差异无统计学意义（P ＞ 0.05）；乳腺癌组织中NGF、CD3+、CD4+、CD8+及CD4+/CD8+水平在肿瘤最大径、病理分级、分化程度及淋巴结转移方面比较，差异均有统计学意义（P ＜ 0.05）；Pearson相关性分析显示：NGF、CD8+水平与肿瘤最大径、病理分级、分化程度及淋巴结转移呈正相关（P ＜ 0.05）；CD3+、CD4+及CD4+/CD8+水平与肿瘤最大径病理分级、分化程度及淋巴结转移呈负相关（P ＜ 0.05）。结论 NGF在乳腺癌患者中呈高表达，导致机体细胞免疫水平下降，且二者表达水平与病理特征具有相关性，加强NGF及细胞免疫水平测定能评估患者疾病严重程度，指导临床治疗。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王文慧1 温媛媛2 陈豪1

关键词 ：血清神经生长因子, 细胞免疫水平, 乳腺癌, 病理特征, 相关性, 酶联免疫吸附试验, 流式细胞仪

Abstract：Objective To investigate the expression of serum nerve growth factor (NGF) and cellular immunity in breast cancer patients and its correlation with clinicopathological feature. Methods A total of 49 breast cancer patients diagnosed in Hangzhou Maternity Hospital and Zhejiang Zhoushan Hospital from March 2015 to February 2018 were selected as the observation group. A total of 45 patients with benign breast disease who were hospitalized at the same time were selected as the control group. A total of 47 female patients with physical examination at the same time were selected as the normal group. The expression levels of NGF in each group were determined by enzyme-linked immunosorbent assay. The levels of CD3+, CD4+, CD8+ and CD4+/CD8+ in each group were determined by flow cytometry. The clinicopathological data of the patients were recorded and counted. The levels of NGF and cellular immunity in each group and the levels of NGF and cellular immunity in different clinicopathological data of breast cancer in the observation group were analyzed. The correlation between NGF, cellular immunity level and clinicopathological data of breast cancer patients was analyzed by Pearson analysis. Results The levels of NGF and cellular immunity in the three groups were statistically significant (P ＜ 0.05). The level of NGF in the observation group was higher than that in the control group and the normal group, and the level of NGF in the control group was higher than that in the normal group, with statistically significant differences (P ＜ 0.05). The levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were lower than those in the control group and the normal group, and the level of CD8+ was higher than that in the control group and the normal group, with statistically significant differences (P ＜ 0.05). There was no significant difference in the levels of CD3+, CD4+, CD8+ and CD4+/CD8+ between the control group and the normal group (P ＞ 0.05). The levels of NGF, CD3+, CD4+, CD8+ and CD4+/CD8+ in breast cancer tissues were not statistically significant differences in terms of age and histopathological type (P ＞ 0.05). The levels of NGF, CD3+, CD4+, CD8+ and CD4+/CD8+ in breast cancer tissues were compared in terms of tumor maximum diameter, pathological grading, differentiation degree and lymph node metastasis, with statistically significant differences (P ＜ 0.05). The Pearson correlation analysis results showed that the NGF and CD8+ levels were positively correlated with the maximum tumor diameter, pathological grading, differentiation degree and lymph node metastasis (P ＜ 0.05). The levels of CD3+, CD4+ and CD4+/CD8+ were negatively correlated with the maximum tumor diameter, pathological grading, differentiation degree and lymph node metastasis (P ＜ 0.05). Conclusion The high expression of NGF in breast cancer patients leads to the decline of cellular immunity level in the body, and the expression level of both is correlated with the pathology feature. Strengthening the determination of NGF and cellular immunity level can assess the severity of the disease in patients and guide clinical treatment.

Key words： Serum nerve growth factor Cellular immunity level Breast cancer Pathology feature Correlation Enzyme-linked immunosorbent assay Flow cytometry

基金资助:浙江省自然科学基金项目（LY16H160058）。

引用本文:

王文慧1 温媛媛2 陈豪1. 血清神经生长因子及细胞免疫水平在乳腺癌中的表达及其与临床病理特征的相关性[J]. 中国医药导报, 2020, 17(11): 88-92.
WANG Wenhui1 WEN Yuanyuan2 CHEN Hao1. Expression of serum nerve growth factor and cellular immunity in breast cancer and its correlation with clinicopathological feature. 中国医药导报, 2020, 17(11): 88-92.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2020/V17/I11/88

[1] 张季，李杨，杨思原，等.乳腺癌患者血清神经生长因子和低亲和力受体p75表达水平的变化及其意义[J].中国普通外科杂志，2017，26（11）：1498-1501.
[2] 李福喜，邵文凤，唐芮，等.埃兹蛋白477位酪氨酸的磷酸化在神经生长因子前体促进乳腺癌细胞侵袭中起关键作用[J].南方医科大学学报，2016，36（7）：898-903.
[3] Zhu J，Zhang XR，Yang H. Effects of combined epidural and general anesthesia on intraoperative hemodynamic responses，postoperative cellular immunity，and prognosis in patients with gallbladder cancer：A randomized controlled trial [J]. Medicine（Baltimore），2017，96（10）：e6137.
[4] 吴立春，谷仕艳，代黄梅，等.长链非编码RNA-ROR在乳腺癌患者血清、癌组织中的表达变化及其临床意义[J].山东医药，2017，57（32）：78-80.
[5] Xiao Z，Wang C，Sun Y，et al. Can Aidi injection restore cellular immunity and improve clinical efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy. A meta-analysis of 17 randomized controlled trials following the PRISMA guidelines [J]. Medicine（Baltimore），2016，95（44）：e5210.
[6] Chen X，Yin B，Lian RC，et al. Modulatory effects of vitamin D on peripheral cellular immunity in patients with recurrent miscarriage [J]. Am J Reprod Immunol，2016，76（6）：432-438.
[7] 王松，薛文华，赵晓玉，等.多西他赛、表柔比星联合环磷酰胺对不同分子分型乳腺癌患者临床疗效及肿瘤标志物表达的影响[J].中国药房，2017，28（23）：3212-3216.
[8] 刘玉芳，李琳，许岩垒，等.三黄煎剂联合新辅助化疗对乳腺癌的近期疗效及对Survivin及Ki-67表达的影响[J].中药材，2016，39（9）：2143-2146.
[9] Gruber IV，Hartkopf AD，Hahn M，et al. Relationship Between Hematogenous Tumor Cell Dissemination and Cellular Immunity in DCIS Patients [J]. Anticancer Res，2016， 36（5）：2345-2351.
[10] Lundgren S，Lyden E，Burdorf A，et al. Left ventricular assist device does not improve cellular immunity in end-stage heart failure[J]. J A Coll Cardiol，2018，71（11）：A950.
[11] Grifoni A，Angelo M，Sidney J，et al. Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 （Tonga/74）Support Its Suitability as a Human Dengue Virus Challenge Strain [J]. J Virol，2017，91（8）. pii：e02133-16.
[12] 李杰宝，喻晓程，田野，等.果蝇zeste基因增强子同源物2在乳腺癌组织中的表达及其与乳腺癌分子分型的相关性[J].中华实验外科杂志，2016，33（9）：2196-2199.
[13] 王博，王宇，胡少军，等.卡培他滨联合多西他赛对乳腺癌肝转移患者血管内皮生长因子、肝细胞生长因子及预后的影响[J].中国免疫学杂志，2017，33（11）：1706-1708，1712.
[14] 钱朋飞，张树平，邓素华，等.尿多酸肽联合化疗对乳腺癌患者免疫功能的影响[J].中华肿瘤防治杂志，2016， 23（19）：1307-1311.
[15] 张楠，孙刚，马斌林.散发性乳腺癌患者乳腺癌易感基因1mRNA与蛋白的表达变化差异及意义[J].中华实验外科杂志，2016，33（4）：884-887.
[16] Khaled AR，Limaye A，Bassiouni R，et al. Abstract P4-04-12：Enhancing the immunogenicity of breast cancer cells to stimulate innate immunity and augment the effects of cellular immunotherapy [J]. Cancer Res，2016，76（4 Supplement）：P4-04-12-P4-04-12.
[17] 金妍.细胞免疫功能检测在乳腺癌临床分期及预后评估中的价值分析[J].中国现代医生，2019，57（12）：124-126.
[18] 程枫，朱磊，陈欢，等.富含半胱氨酸分泌性酸性蛋白在乳腺癌组织中的表达及其临床意义[J].中国临床药理学杂志，2017，33（1）：18-20.
[19] Cook KL，Soto-Pantoja DR，Clarke PA，et al. Endoplasmic reticulum stress protein GRP78 modulates lipid metabolism to control drug sensitivity and anti-tumor immunity in breast cancer [J]. Cancer Res，2016，76（19）：5657-5670.
[20] 郭崇勇，丁宝忠，李柏成，等.三阴性乳腺癌组织中ALDH1、TGF-β_1蛋白的表达变化及其对预后的影响[J].山东医药，2017，57（46）：61-63.
[21] 曾榃伦，吕铮，崔久嵬，等.肿瘤浸润淋巴细胞在三阴性乳腺癌疗效预测及预后评估中作用的研究进展[J].中国医药，2018，13（7）：1103-1106.
[22] 周玉冰，殷德涛，李朵璐，等.细胞周期蛋白依赖性激酶11在乳腺癌组织中的表达及临床意义[J].中华实验外科杂志，2016，33（3）：639-642.